IDXG

Interpace Biosciences, Inc. [IDXG] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

IDXG Stock Summary

In the News

09:15 04 Mar 2024 IDXG

Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank

PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $7.5 Million revolving credit facility with Comerica Bank (the “Bank”). The facility matures on September 30, 2023 and allows for advances based on 80% of eligible accounts receivable plus an applicable non-formula amount consisting of $2,000,000 of additional availability at close, stepping down $250,000 per quarter beginning with the quarter ending June 30, 2022. The interest rate is equal to prime plus .50%, prime being the greater of the bank's stated prime rate or the sum of the daily adjusting LIBOR rate, plus 2.5% per annum. The Bank will have a first priority security interest in substantially all of Interpace's and its subsidiaries' assets and will be senior to the existing $7.5 Million bridge loans made by the Company's private equity investors.

09:36 04 Mar 2024 IDXG

Interpace Biosciences, Inc. (IDXG) Reports Q2 Loss, Tops Revenue Estimates

Interpace Biosciences, Inc. (IDXG) delivered earnings and revenue surprises of -72.92% and 0.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

09:46 04 Mar 2024 IDXG

Interpace Biosciences, Inc. (IDXG) Is a Great Choice for "Trend" Investors, Here's Why

Interpace Biosciences, Inc. (IDXG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

04:47 04 Mar 2024 IDXG

Interpace Biosciences Announces First Quarter 2021 Financial and Business Results

PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 and provided a business and financial update.

07:05 04 Mar 2024 IDXG

Interpace Biosciences Raises Full Year 2021 Revenue Guidance

Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally provided on March 31, 2021.

07:05 04 Mar 2024 IDXG

Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis

Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in advancing RNA biomarker analysis for gene and cell-based therapies.

04:05 04 Mar 2024 IDXG

Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®

Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has agreed to recognize the new Proprietary Laboratory Analysis (PLA) code that specifically identifies ThyGeNEXT® as a distinct test from any other test or service. PLA codes are an addition to the current procedural terminology (CPT®) code set approved by the American Medical Association CPT® Editorial Panel. PLA codes are alpha-numeric CPT codes with a corresponding descriptor for labs that want to more specifically identify their test. The new PLA code for ThyGeNEXT® is 0245U and the reimbursement for this code remains $2,919, representing a significant price increase over the prior reimbursement level of $560. In December, 2020, Novitas issued a new local coverage determination (LCD) for ThyGeNEXT® that reflects the test's enhanced mutation panel. In 2020, Interpace processed approximately 15,000 ThyGeNEXT® tests for over 700 physicians.

05:20 04 Mar 2024 IDXG

Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results

PARSIPPANY, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended December 31, 2020 and provided a business and financial update.

07:30 04 Mar 2024 IDXG

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR

Part of Company's Site Consolidation and Cost Savings Measures

04:31 04 Mar 2024 IDXG

Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois

In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer

IDXG Financial details

Company Rating
Neutral
Market Cap
4.52M
Income
-1.5M
Revenue
38.26M
Book val./share
-14.51
Cash/share
1.17
Dividend
-
Dividend %
-
Employees
94
Optionable
No
Shortable
Yes
Earnings
25 Mar 2024
P/E
-2.98
Forward P/E
-
PEG
0.33
P/S
0.12
P/B
-0.28
P/C
0.9
P/FCF
3.45
Quick Ratio
0.8
Current Ratio
0.93
Debt / Equity
-0.22
LT Debt / Equity
-0.21
-
-
EPS (TTM)
-0.35
EPS next Y
-
EPS next Q
1.58
EPS this Y
-61.34%
EPS next Y
-
EPS next 5Y
-57.14%
EPS last 5Y
-20.44%
Revenue last 5Y
7.77%
Revenue Q/Q
-17.67%
EPS Q/Q
-450%
-
-
-
-
SMA20
1.92%
SMA50
-0.93%
SMA100
10.42%
Inst Own
0.3%
Inst Trans
0.05%
ROA
-10%
ROE
3%
ROC
0.85%
Gross Margin
60%
Oper. Margin
4%
Profit Margin
-4%
Payout
-
Shs Outstand
4.32M
Shs Float
3.16M
-
-
-
-
Target Price
-
52W Range
0.6203-3.54
52W High
-
52W Low
-
RSI
51.02
Rel Volume
0.42
Avg Volume
4.95K
Volume
2.06K
Perf Week
0%
Perf Month
14.13%
Perf Quarter
0%
Perf Half Y
-4.46%
-
-
-
-
Beta
0.59
-
-
Volatility
0.02%, 0.05%
Prev Close
0%
Price
1.05
Change
0%

IDXG Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
7.786.438.049.997.51
Net income per share
-4.33-7.11-6.5-3.57-1.38
Operating cash flow per share
-3.08-5.06-3.62-2.11-1.82
Free cash flow per share
-3.24-5.1-4.01-2.19-1.89
Cash per share
2.150.620.690.81.14
Book value per share
11.73.48-7.22-10.26-14.88
Tangible book value per share
1.1-7.72-12.13-14.06-15.09
Share holders equity per share
11.73.48-7.22-10.26-14.88
Interest debt per share
0.122.011.313.544.03
Market cap
22.53M18.73M12.65M30.89M4.41M
Enterprise value
16.46M23.51M14.62M41.29M15.67M
P/E ratio
-1.85-0.7-0.48-2.09-0.75
Price to sales ratio
1.030.780.390.750.14
POCF ratio
-2.6-0.99-0.87-3.54-0.57
PFCF ratio
-2.47-0.98-0.78-3.4-0.55
P/B Ratio
0.681.44-0.43-0.73-0.07
PTB ratio
0.681.44-0.43-0.73-0.07
EV to sales
0.750.980.4510.49
Enterprise value over EBITDA
-2.32-1.17-0.68-5.05-4.14
EV to operating cash flow
-1.9-1.24-1-4.74-2.04
EV to free cash flow
-1.8-1.23-0.91-4.55-1.96
Earnings yield
-0.54-1.42-2.07-0.48-1.33
Free cash flow yield
-0.4-1.02-1.28-0.29-1.82
Debt to equity
00.54-0.16-0.32-0.26
Debt to assets
00.10.10.361.01
Net debt to EBITDA
0.86-0.24-0.09-1.27-2.98
Current ratio
2.090.950.770.780.85
Interest coverage
-36.61-54.39-48.37-12.76-3.81
Income quality
0.710.710.550.580.35
Dividend Yield
00000.68
Payout ratio
0000-0.51
Sales general and administrative to revenue
0.390.60.640.330.34
Research and developement to revenue
0.10.120.090.050.02
Intangibles to total assets
0.620.610.430.410.05
Capex to operating cash flow
0.050.010.110.040.04
Capex to revenue
-0.02-0.01-0.05-0.01-0.01
Capex to depreciation
-0.13-0.03-0.29-0.07-0.13
Stock based compensation to revenue
0.10.060.070.030.04
Graham number
33.7523.5932.528.6921.53
ROIC
-0.37-0.991.360.460.09
Return on tangible assets
-0.66-0.98-1.01-0.65-0.39
Graham Net
-0.61-12.05-16.12-17.42-16.48
Working capital
9.23M-929K-4.11M-3.52M-2.13M
Tangible asset value
3.09M-28.91M-48.87M-58.14M-63.93M
Net current asset value
2.22M-39.66M-60.64M-68.68M-66.9M
Invested capital
00.54-0.16-0.32-0.26
Average receivables
6.46M9.84M9.11M7.09M5.6M
Average payables
725K2.94M4.66M3.6M1.87M
Average inventory
748K1.53M1.94M1.92M1.51M
Days sales outstanding
158.08154.5790.4454.457.69
Days payables outstanding
37.91110.5575.9742.0828.17
Days of inventory on hand
44.0341.9334.5627.932.83
Receivables turnover
2.312.364.046.716.33
Payables turnover
9.633.34.88.6712.96
Inventory turnover
8.298.7110.5613.0811.12
ROE
-0.37-2.050.90.350.09
Capex per share
-0.16-0.03-0.39-0.09-0.08

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.931.952.282.552.1
Net income per share
-0.3-0.330.080.04-0.14
Operating cash flow per share
-0.76-0.060.260.10.26
Free cash flow per share
-0.77-0.110.250.070.22
Cash per share
1.491.131.31.181.17
Book value per share
-14.52-14.77-14.52-14.41-14.51
Tangible book value per share
-14.8-14.97-14.64-14.47-14.52
Share holders equity per share
-14.52-14.77-14.52-14.41-14.51
Interest debt per share
3.213.833.693.513.19
Market cap
9.33M4.44M4.78M4.75M4.06M
Enterprise value
16.36M15.7M14.81M14.56M12.56M
P/E ratio
-1.86-0.793.416.78-1.65
Price to sales ratio
1.140.530.490.430.45
POCF ratio
-2.88-16.094.2211.553.67
PFCF ratio
-2.84-9.414.4815.834.26
P/B Ratio
-0.15-0.07-0.08-0.08-0.06
PTB ratio
-0.15-0.07-0.08-0.08-0.06
EV to sales
21.881.511.321.38
Enterprise value over EBITDA
-45.2-21.4814.114.3456.08
EV to operating cash flow
-5.04-56.913.0735.4411.37
EV to free cash flow
-4.98-33.2713.8748.5513.18
Earnings yield
-0.13-0.320.070.04-0.15
Free cash flow yield
-0.35-0.110.220.060.23
Debt to equity
-0.22-0.26-0.25-0.24-0.22
Debt to assets
0.871.010.980.930.95
Net debt to EBITDA
-19.42-15.419.559.6637.96
Current ratio
0.860.850.90.960.93
Interest coverage
-2.910.542.63.21-0.06
Income quality
0.230.183.232.35-2.09
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.340.280.250.260.23
Research and developement to revenue
0.020.010.020.020.02
Intangibles to total assets
0.080.050.030.010
Capex to operating cash flow
0.010.71-0.06-0.27-0.14
Capex to revenue
0-0.02-0.01-0.01-0.02
Capex to depreciation
-0.06-0.55-0.18-0.31-0.63
Stock based compensation to revenue
0.060.020.020.010.02
Graham number
9.8310.465.163.636.81
ROIC
0.020-0.01-0.020
Return on tangible assets
-0.09-0.090.020.01-0.04
Graham Net
-15.64-16.35-15.95-15.83-15.68
Working capital
-2.07M-2.13M-1.37M-590K-886K
Tangible asset value
-62.77M-63.93M-63.08M-62.43M-62.71M
Net current asset value
-64.15M-66.9M-65.93M-65.17M-65.49M
Invested capital
-0.22-0.26-0.25-0.24-0.22
Average receivables
5.62M4.91M4.87M5.12M5.18M
Average payables
2.48M1.25M1.32M1.64M1.52M
Average inventory
1.63M1.24M1.2M1.18M1.14M
Days sales outstanding
52.6754.3543.1945.1347.88
Days payables outstanding
37.6528.463736.2728.15
Days of inventory on hand
32.4433.1727.4625.2822.76
Receivables turnover
1.711.662.081.991.88
Payables turnover
2.393.162.432.483.2
Inventory turnover
2.772.713.283.563.96
ROE
0.020.02-0.0100.01
Capex per share
-0.01-0.05-0.02-0.03-0.04

IDXG Frequently Asked Questions

What is Interpace Biosciences, Inc. stock symbol ?

Interpace Biosciences, Inc. is a US stock , located in Parsippany of Nj and trading under the symbol IDXG

What is Interpace Biosciences, Inc. stock quote today ?

Interpace Biosciences, Inc. stock price is $1.05 today.

Is Interpace Biosciences, Inc. stock public?

Yes, Interpace Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Similar Market Cap